

Resource Summary Report

Generated by [nidm-terms](#) on Aug 9, 2026

European Federation of Pharmaceutical Industries and Associations

RRID:SCR_003820

Type: Tool

Proper Citation

European Federation of Pharmaceutical Industries and Associations (RRID:SCR_003820)

Resource Information

URL: <http://www.efpia.eu/>

Proper Citation: European Federation of Pharmaceutical Industries and Associations (RRID:SCR_003820)

Description: Federation representing the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, it is the voice on the EU scene of 1,900 companies committed to researching, developing and manufacturing new medical treatments. In addition, it is active in partnering in EU Research programmes, such as the IMI (Innovative Medicines Initiative), Europe's largest public-private partnerships. They also work on corporate social responsibility initiatives with others healthcare stakeholders, such as patient groups and healthcare professionals. EFPIA has specialized committees and task forces focused on key areas of activity. EFPIA also includes two specialized groups focusing on vaccines and biotechnology, respectively: * Vaccines Europe (formerly European Vaccine Manufacturers, EVM) produces approximately 80% of vaccines used worldwide * European Biopharmaceutical Enterprises (EBE) harness biotechnology to develop approximately one-fifth of new medicines

Abbreviations: EFPIA

Resource Type: institution

Keywords: pharmaceutical, medicine, vaccine, biotechnology, manufacturing, corporate

Resource Name: European Federation of Pharmaceutical Industries and Associations

Resource ID: SCR_003820

Alternate IDs: nlx_158124, grid.484123.8, ISNI: 0000 0000 9246 8110, Wikidata: Q1376562

Alternate URLs: <https://ror.org/00g1x4v36>

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260808T185804+0000

Ratings and Alerts

No rating or validation information has been found for European Federation of Pharmaceutical Industries and Associations.

No alerts have been found for European Federation of Pharmaceutical Industries and Associations.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Tshilumba SM, et al. (2026) Plasmodium falciparum Malaria and Arbovirus Co-Exposure in the Boende Health Zone, Northwestern Democratic Republic of the Congo. Tropical medicine and infectious disease, 11(5).

Esser MJ, et al. (2026) Flow Cytometric Assessment of Pertactin- and Tetanus Toxoid-Specific B-Cell Kinetics After Tdap Booster Vaccination in Healthy Adults. Vaccines, 14(4).

D'Anna S, et al. (2026) Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity. Viruses, 18(5).

Zwiers LC, et al. (2025) Remote early detection of SARS-CoV-2 infections using a wearable-based algorithm: Results from the COVID-RED study, a prospective randomised single-blinded crossover trial. PloS one, 20(6), e0325116.

Kasonia K, et al. (2025) Regulator experiences of trials during Ebola epidemics in Sierra Leone, Guinea, and the Democratic Republic of the Congo. Tropical medicine & international health : TM & IH, 30(6), 539.

Toropova AP, et al. (2025) Simulation of Fish Acute Toxicity of Pharmaceuticals Using Simplified Molecular Input Line Entry System (SMILES) Notation as a Representation of Molecular Structure. International journal of molecular sciences, 26(19).

van Vredendaal R, et al. (2025) Assessing Ebola virus circulation in the Tshuapa province (Democratic Republic of the Congo): A One Health investigation of wildlife and human interactions. PLoS pathogens, 21(11), e1013628.

Baird AM, et al. (2023) How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action. *Health science reports*, 6(6), e1349.

Zola Matuvanga T, et al. (2023) Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo. *PloS one*, 18(9), e0286479.

Mayr F, et al. (2022) Improving Small Molecule pK_a Prediction Using Transfer Learning With Graph Neural Networks. *Frontiers in chemistry*, 10, 866585.

Kayhan H, et al. (2022) Ensuring Trust in Pharmaceutical Supply Chains by Data Protection by Design Approach to Blockchains. *Blockchain in healthcare today*, 5.

Brakenhoff TB, et al. (2021) A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial. *Trials*, 22(1), 412.

Selvaraj EA, et al. (2021) Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *Journal of hepatology*, 75(4), 770.

Hemmerich J, et al. (2020) In silico toxicology: From structure-activity relationships towards deep learning and adverse outcome pathways. *Wiley interdisciplinary reviews. Computational molecular science*, 10(4), e1475.

De Sousa PA, et al. (2017) Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience. *Stem cell research*, 20, 105.

Pozniak E, et al. (2016) State of play of CME in Europe in 2015: Proceedings from the Eighth Annual European CME Forum. *Journal of European CME*, 5(1), 32174.

Soto-Rey I, et al. (2015) User Satisfaction Evaluation of the EHR4CR Query Builder: A Multisite Patient Count Cohort System. *BioMed research international*, 2015, 801436.

Alrifaiy A, et al. (2015) A lab-on-a-chip for hypoxic patch clamp measurements combined with optical tweezers and spectroscopy- first investigations of single biological cells. *Biomedical engineering online*, 14, 36.

Che SP, et al. (2015) Tissue factor-expressing tumor cells can bind to immobilized recombinant tissue factor pathway inhibitor under static and shear conditions in vitro. *PloS one*, 10(4), e0123717.

Nguyen VA, et al. (2009) Endothelial cells from cord blood CD133+CD34+ progenitors share phenotypic, functional and gene expression profile similarities with lymphatics. *Journal of cellular and molecular medicine*, 13(3), 522.